Torre, L. A. et al. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 68, 284–296 (2018).
PubMed PubMed Central Article Google Scholar
Narod, S. Can advanced-stage ovarian cancer be cured? Nat. Rev. Clin. Oncol. 13, 255–261 (2016).
CAS PubMed Article Google Scholar
Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719–725 (2011).
CAS PubMed PubMed Central Article Google Scholar
Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
CAS PubMed Article Google Scholar
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
CAS PubMed Article Google Scholar
Ovarian Tumor Tissue Analysis, C. et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 3, e173290 (2017).
Hwang, W. T., Adams, S. F., Tahirovic, E., Hagemann, I. S. & Coukos, G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 124, 192–198 (2012).
Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
CAS PubMed Article Google Scholar
Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008).
CAS PubMed Article Google Scholar
George, J. et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin. Cancer Res. 19, 3474–3484 (2013).
CAS PubMed Article Google Scholar
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
PubMed Central Article CAS Google Scholar
Verhaak, R. G. et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123, 517–525 (2013).
Chen, G. M. et al. Consensus on molecular subtypes of high-grade serous ovarian carcinoma. Clin. Cancer Res. 24, 5037–5047 (2018).
PubMed PubMed Central Article Google Scholar
Hanker, L. C. et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann. Oncol. 23, 2605–2612 (2012).
CAS PubMed Article Google Scholar
Bamias, A. et al. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Ann. Oncol. 28, 1842–1848 (2017).
CAS PubMed Article Google Scholar
Markman, M. The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy. Ann. Oncol. 22, viii69–viii71 (2011).
Hamanishi, J. et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015–4022 (2015).
CAS PubMed Article Google Scholar
Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080–1087 (2019).
CAS PubMed Article Google Scholar
Duraiswamy, J. et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell https://doi.org/10.1016/j.ccell.2021.10.008 (2021).
Hornburg, M. et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell 39, 928–944 e926 (2021).
CAS PubMed Article Google Scholar
Olalekan, S., Xie, B., Back, R., Eckart, H. & Basu, A. Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics. Cell Rep. 35, 109165 (2021).
CAS PubMed Article Google Scholar
Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
CAS PubMed Article Google Scholar
Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44–55 (2014).
CAS PubMed Article Google Scholar
Webb, J. R., Milne, K., Watson, P., Deleeuw, R. J. & Nelson, B. H. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin. Cancer Res. 20, 434–444 (2014).
CAS PubMed Article Google Scholar
Webb, J. R., Milne, K. & Nelson, B. H. PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer. Cancer Immunol. Res. 3, 926–935 (2015).
CAS PubMed Article Google Scholar
Eiva, M. A., Omran., D. K., Chacon, J. & Powell, D. J. Jr Systematic analysis of CD39, CD103, CD137 and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs. Preprint at bioRxiv https://doi.org/10.1101/2021.03.29.437255 (2021).
Desbois, M. et al. Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat. Commun. 11, 5583 (2020).
CAS PubMed PubMed Central Article Google Scholar
Anadon, C. M. et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell https://doi.org/10.1016/j.ccell.2022.03.008 (2022).
Zhang, A. W. et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell 173, 1755–1769 e1722 (2018).
CAS PubMed Article Google Scholar
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
CAS PubMed PubMed Central Article Google Scholar
Bobisse, S. et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer. Nat. Commun. 9, 1092 (2018).
PubMed PubMed Central Article CAS Google Scholar
Liu, S. et al. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J. Immunother. Cancer 7, 156 (2019).
PubMed PubMed Central Article Google Scholar
D’Angelo, S. P. et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1c259T cells in synovial sarcoma. Cancer Discov. 8, 944–957 (2018).
PubMed PubMed Central Article CAS Google Scholar
Siddiqui, I. et al. Intratumoral Tcf1+ PD-1+ CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211 e110 (2019).
CAS PubMed Article Google Scholar
Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019).
CAS PubMed PubMed Central Article Google Scholar
Kroeger, D. R., Milne, K. & Nelson, B. H. Tumor-Infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 22, 3005–3015 (2016).
CAS PubMed Article Google Scholar
Conejo-Garcia, J. R., Rutkowski, M. R. & Cubillos-Ruiz, J. R. State-of-the-art of regulatory dendritic cells in cancer. Pharmacol. Ther. 164, 97–104 (2016).
CAS PubMed PubMed Central Article Google Scholar
Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527–1538 (2015).
CAS PubMed PubMed Central Article Google Scholar
Chopra, S. et al. IRE1alpha-XBP1 signaling in leukocytes controls prostaglandin biosynthesis and pain. Science https://doi.org/10.1126/science.aau6499 (2019).
留言 (0)